Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
asvasiran
- Development stage
- Phase 2
- Lead developer
- Alnylam Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation, Intranasal
01
Overview
Asvasiran is a small interfering RNA (siRNA) therapeutic developed for the treatment or prevention of respiratory syncytial virus (RSV) infection. It specifically targets the nucleocapsid (N) gene of RSV and inhibits viral replication through RNA interference. The drug was developed by Alnylam Pharmaceuticals and has been investigated in both intranasal and aerosolized formulations. Its mechanism involves modulating the nucleocapsid protein via sequence-specific mRNA degradation, thereby preventing production of essential viral proteins required for replication[1][2][3][4][5]. Development was suspended after reaching Phase II clinical trials for RSV infections[3][5].
- Other names
- asvasiran sodiumaerosolised ALN-RSV01intranasal ALN-RSV01
02
Targets
RSV N (Respiratory syncytial virus nucleoprotein)
Beyond the preview
Go deeper on asvasiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on asvasiran.